IL6 and COVID-19: Although three neutralizing antibodies that target IL‐6 signalling are being evaluated for efficacy as COVID‐19 therapeutics (Solis‐Garcia Del Pozo et al., 2020), we took an approach of drug repurposing to validate the effect of nasal inoculation of LCC on NPP‐induced IL‐6.